KR20230120267A - A novel lactobacillus gaseri GFC_1220 strain with anti-inflammatory and antibacterial effects and fermented products prepared using it - Google Patents

Abstract

The present invention relates to a novel Lactobacillus gasseri GFC_1220 (Accession Number: KCTC13840BP) strain, and a fermented product prepared using the same.
Induction of skin-microbiome changes in the culture medium of the novel Lactobacillus gasseri GFC_1220 strain (accession number: KCTC13840BP) provided by the present invention (reduction of inflammatory S. aures strains), Since it has excellent anti-inflammatory and antibacterial effects, it has excellent effects as a cosmetic composition when applied to a cosmetic base as an active ingredient.

Description

A novel lactobacillus gaseri GFC_1220 strain with anti-inflammatory and antibacterial effects and fermented products prepared using it

The present invention relates to a novel Lactobacillus gasseri GFC_1220 having anti-inflammatory and antibacterial effects and a fermented product prepared using the same.

The ecosystem of the skin provides various types of habitats for microorganisms, and a wide range of microorganisms live there. The human host forms a symbiotic relationship with them and is known to have many positive effects on the host. The skin constitutes various types of habitats, such as indentations and specialized crevices, and helps a wide range of microorganisms to grow. Basically, the skin forms a physical barrier and helps to defend against potential risk factors and toxic substances from the outside. The skin becomes a point of contact with the external environment and is also a gathering place for various microorganisms (fungi, bacteria, viruses, and small larvae). Depending on the selection of physical and chemical functions, microorganisms adapt and establish habitats in specialized niches. In general, the skin is cold, has an acidic nature, and remains dry. Structurally, the epidermis forms the skin barrier, blocks the penetration of microorganisms and toxins, and plays an important role in maintaining moisture. The uppermost layer of the epidermis is composed of the stratum corneum and differentiated from keratinocytes. The epidermis has a form called a so-called “brick and mortar structure”. The skin tissue undergoes a continuous self-healing process, and the squames that have passed through the end of the differentiation process repeat the process of being constantly eliminated from the skin tissue.

Meanwhile, bacteria that obtain energy by fermenting sugars and produce a large amount of lactic acid are collectively referred to as lactic acid bacteria. Lactic acid bacteria live in the intestines and live in symbiosis with the digestive system of the human body, and play a role in breaking down fiber and complex proteins into important nutrients. In addition, by keeping the intestinal environment acidic, it inhibits the growth of harmful bacteria, improves diarrhea and constipation, synthesizes vitamins, and lowers blood cholesterol. Lactic acid bacteria have the property of being able to bind strongly to intestinal mucosa and epithelial cells, so they help a lot in the intestinal function, and promote the activity of macrophages and spleen to secrete and promote substances involved in the immune response. In addition, it has an immunomodulatory function, so it is effective for atopy and allergy-related diseases.

In the field of cosmetics, lactobacillus culture medium has been commercialized in 1955 and has been used until now, mainly Streptococcus, Lactobacillus , Lactococcus , Leuconostoc , and Bifidobacterium. ( Bifidobacterium ) Researches are being actively conducted such as filtering or extracting by directly fermenting the culture medium using the genus, etc., and filtering or extracting after inoculating and fermenting the raw material form and active material.

Among them, as a technology applied to various uses using the genus Lactobacillus , Korean Patent Registration No. 10-1801764 "Lactobacillus cabetus WIKIN55 having hair promoting activity and a composition containing the same, Korean registered patent Publication No. 10-2137252, “Mixed fermented extract for preventing stress-induced hair loss using strain Lactobacillus plantanum J2K-27, manufacturing method thereof, and cosmetic composition containing the mixed fermented extract” and the like are disclosed.

Looking back at the skin ecological environment, physical and biological factors are well harmonized to provide various habitats, and furthermore, we can think about the delicate balance between humans and microbes. When the balance of the symbiotic relationship collapses, skin breakdown and infection occur at the same time.

Accordingly, the present inventors isolated and identified the Lactobacillus gasseri GFC_1220 strain (accession number: KCTC13840BP), and used it to inoculate the MRS medium and prepare a fermented product through the culturing step, scalp- The present invention was completed by discovering that it could induce skin-microbiome changes (reduction of inflammatory S. aureus strains) and reduce inflammation.

An object of the present invention is to provide a novel strain having skin-microbiome change induction (reduction of inflammatory S. aureus strains), inflammation reduction and antibacterial effect.

Another object of the present invention is to provide a method for producing a fermented product comprising the step of inoculating and culturing a novel strain in a medium formulated to maximize efficacy and activity, and a fermented product prepared therefrom.

Another object of the present invention is to provide a cosmetic composition comprising a fermented product of a novel strain as an active ingredient.

In order to achieve the above object, the present invention induces skin-microbiome changes (reduction of inflammatory S. aureus strains), reduces inflammation, and Lactobacillus gasseri GFC_1220 having antibacterial effects. ( Lactobacillus gasseri GFC_1220) strain (accession number: KCTC13840BP) is provided.

In the present invention, the strain is characterized in that it is derived from breast milk.

In addition, the present invention inoculates the Lactobacillus gasseri GFC_1220 strain (accession number: KCTC13840BP) into a medium formulated to maximize efficacy activity, and a method for producing a fermented product comprising the step of culturing to provide.

In the present invention, the medium is characterized in that it contains Maltose, Lactose, Glycine, Inulin.

In addition, in the present invention, the culture is characterized in that it is carried out for 90 to 130 hours at 32 ~ 37 ℃.

In addition, the present invention provides a fermented product fermented with the Lactobacillus gasseri GFC_1220 strain (Accession Number: KCTC13840BP).

In addition, the present invention provides a cosmetic composition comprising the fermented product as an active ingredient.

In the present invention, the cosmetic composition is characterized in that it is selected from the group consisting of skin-microbiome change induction (reduction of inflammatory S. aureus strains) and inflammation reduction effect .

The Lactobacillus gasseri GFC_1220 strain (accession number: KCTC13840BP) provided by the present invention induces skin-microbiome changes (reduction of inflammatory S. aureus strains) and reduces inflammation Since the effect is excellent, the effect as a cosmetic composition is excellent when applied to a cosmetic base as an active ingredient.

1 shows the nucleotide sequence of the Lactobacillus gasseri GFC_1220 strain (accession number: KCTC13840BP) according to the present invention.
Figure 2 shows the reduction change of S. aureus when the fermented product of the Lactobacillus gasseri GFC_1220 strain (accession number: KCTC13840BP) according to the present invention is treated on the skin.
Figure 3 is a graph showing anti-inflammation by inflammatory cytokine regulation of the fermentation product of the Lactobacillus gasseri GFC_1220 strain (accession number: KCTC13840BP) according to the present invention.

Therefore, in the present invention, strains having an effect of inducing skin-microbiome change (reduction of inflammatory S. aureus strains) and reducing inflammation are screened to select excellent strains, and 16s rRNA sequencing analysis As a result, it was confirmed that it was a novel microorganism having a nucleotide sequence similar to that of Lactobacillus gasseri. Accordingly, it was named Lactobacillus gasseri GFC_1220 ( Lactobacillus gasseri GFC_1220) strain and deposited at the Biological Resource Center of Korea Research Institute of Bioscience and Biotechnology.

Accordingly, the present invention relates to the Lactobacillus gasseri GFC_1220 strain (accession number: KCTC13840BP) (hereinafter abbreviated as 'GFC_1220').

At this time, the GFC_1220 strain is characterized in that it is derived from human breast milk.

In addition, the present invention relates to a method for producing a fermented product comprising the steps of inoculating and culturing the GFC_1220 strain in a medium formulated to maximize efficacious activity.

The medium used for the culture is characterized in that it contains Maltose, Lactose, Glycine, and Inulin. Among them, MRS medium (proteose peptone No.3 10g, beef extract 10g, yeast extract 5g, dextrose 20g, polyoxyethylene sorbitan monooleate 1g, ammonium citrate 2g, maganessium sulfate 0.1g, manganesse selfate 0.05g, dipotassium phosphate 2g, sodium acetate 5g/ L, pH 6.5) as a base, and fermented using a medium to which 0.5 g/L of Maltose, 1.0 g/L of Lactose, 0.5 g/L of Glycine, and 1.0 g/L of Inulin were added to improve the yield of the fermentation product most effectively. It is preferable in terms of being able to reduce the inflammation-causing strain.

The GFC_1220 strain was 1.0x10 ⁷ to 1.0x10 7 to MRS liquid medium supplemented with Maltose, Lactose, Glycine and Inulin. The step of inoculating and culturing at a level of 1 to 3% so that the number of bacteria is 1.0x10 ⁹ is characterized by performing stationary culture at 32 to 37 ° C. for 90 to 130 hours in anaerobic conditions. If the incubation temperature and time are out of the above range, the culture conditions of the fermenting strain are not suitable, leading to sufficient skin-microbiome changes (reduction of inflammatory S. aureus strains), reduction of inflammation, and antibacterial activity. Not only can it not show activity, but it is not preferable because it does not propagate strains.

As described above, the cultured strain is filtered under pH 3.8 to 4.2 conditions, and then the filtered strain is aged at 20 to 30 ° C. for 10 to 16 days to prepare a fermented product.

In addition, the fermented product of the Lactobacillus gasseri GFC_1220 strain (accession number: KCTC13840BP) of the present invention induces skin-microbiome changes (reduction of S. aureus strains causing inflammation), inflammation reduction and antibacterial effect, so the effect as a cosmetic composition is very excellent.

Accordingly, the present invention relates to a cosmetic composition comprising a fermented product fermented with Lactobacillus gasseri GFC_1220 strain (Accession Number: KCTC13840BP) as an active ingredient.

The cosmetic composition may be for use selected from the group consisting of skin-microbiome change induction (reduction of inflammatory S. aureus strains), inflammation reduction, and antibacterial effect.

Induction of skin-microbiome change (reduction of inflammatory S. aureus strains), reduction of inflammation, and antibacterial active cosmetic composition of the present invention include external skin ointments, creams, softening lotions, nutrient lotions, packs, Essence, hair tonic, shampoo, conditioner, hair conditioner, hair treatment, gel, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, eye cream, moisture It may have a formulation selected from the group consisting of cream, hand cream, foundation, nutrient essence, sunscreen, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto. The composition of each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these components can be easily selected by those skilled in the art.

When the formulation of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc acid may be used as a carrier component. can

When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane / May contain a propellant such as butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid ester.

When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.

When the formulation of the present invention is surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives, or ethoxylated glycerol fatty acid esters may be used.

In the cosmetic composition for anti-inflammatory and antibacterial enhancing effects of the present invention, the fermented product may be contained in an amount of 0.01 to 90% by weight, preferably 3 to 15% by weight, based on the total weight of the composition. , induction of desirable skin-microbiome changes (reduction of inflammatory S. aureus strains), reduction of inflammation, and an effective amount capable of providing antibacterial effects are not limited thereto.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for explaining the present invention in more detail, and it is to those of ordinary skill in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. It will be self-explanatory.

<Example 1> Lactobacillus gasseri GFC_1220 ( Lactobacillus gasseri Isolation of GFC_1220) strain (accession number: KCTC13840BP) strain

0.1mL of a sample diluted 10 ^-4 times (volume) of 1ml of mother's milk after giving birth was mixed with MRS agar medium (Peptospecial 10 g, beef extract 10g, yeast extract 5g, Glucose 20g, Triammonium Citrate 2g, sodium acetate 5g, maganessium sulfate 0.2 g, manganesse selfate 0.05g, dipotassium phosphate 2g, Agar 15g, Tween80 1g/L, pH 6.2±0.2, MBcell (Cat.No. MB-M1025)) and incubated at 37°C for 2 days in an anaerobic incubator. The formed colonies were cultured in pure separation and cultured in an anaerobic incubator for 24 hours, and then single colonies formed were isolated. Among the isolated strains, the GFC_1220 strain, which has excellent effects of inducing skin-microbiome changes (reduction of inflammatory S. aureus strains), reduction of inflammation, and proliferation of dermal papilla cells, was selected.

<Example 2> Selected strain 16s rRNA sequencing analysis

The gDNA of the finally selected GFC1203H strain and the universal primer SEQ ID NO: 1: 27F (5' AGA GTT TGA TCM TGG CTC AG 3') and SEQ ID NO: 2: 1492R (5' TAC GGY TAC CTT GTT ACG ACT T 3') Through 16s DNA sequencing analysis, it was confirmed that it was a strain with high homology to Lactobacillus gasseri , and it was named as Lactobacillus gasseri GFC_1220 strain and deposited with the International Microbial Patent Depositary and received the accession number KCTC13840BP.

<Example 3> Preparation of fermented product of strain GFC_1220

In order to prepare a fermented product of the separated GFC_1220 strain, Maltose, Lactose, Glycine, and Inulin were added to the MRS medium, and then the GFC_1220 strain was inoculated at 1% to a bacterial count of 1.0x10 ⁹ . After inoculation, there is no oxygen supply so that the anaerobic state is maintained, and stationary culture was carried out at 37 ° C. for 120 hours. After the culture was completed, it was confirmed that the pH was formed at 4.0 (error 0.2), and when it was visually confirmed that the culture was dark brown, the culture was finished and sterilization was performed with a 0.2 μm filter (Millipore). When the filter was completed, the fermented product of the GFC_1220 strain was prepared through an aging period of 2 weeks at room temperature.

<Remarks 2> General Lactobacillus gasseri ( Lactobacillus gasseri ) fermented product using bacteria

Comparative Example 1 was prepared in the same manner as in <Example 3>, except that the Lactobacillus gasseri type strain was used instead of the isolated GFC_1220 strain.

<Experimental Example 1> Subject and Skin Microbiome Sample Collection

The samples used in this experiment were tested on subjects who obtained informed consent from the GFC Life Science Research Institute. The fermented product of the GFC_1220 strain was used as the probiotics used in the test. After culture, the culture medium from which the cells were removed was applied to the subject's facial skin, and skin samples were collected for a total of 72 hours and used for analysis. The collection method was cotton swab The method was used and skin samples were collected by scrubbing using gauze. Skin resident microorganisms were collected in pre-treatment, post-treatment, non-treatment (resting period) and re-treatment groups.

Skin samples were collected using sterilized water and a scraper based on the reference literature, and all work was conducted in a clean bench. This study confirmed that it falls under the reason for exemption from the IRB review criteria.

<Experimental Example 2> Genomic DNA extraction and DNA amplification of skin resident microorganisms

A sample collected from the skin is suspended in 0.85% NaCl, the supernatant is centrifuged (17,000 rpm/m) to obtain cells, and after washing the cells once in sterilized physiological saline, FastDNA SPIN KIT (MP Biomedical, France) is used DNA was extracted.

<Experimental Example 3> Confirmation of inhibition of acne strains among scalp flora through DGGE analysis

D-code system (Bio-rad, USA) was used for DGGE analysis. The polyacrylamide gel concentration used was 8%, and a 40% polyacrylamide bis-solution 29:1 (3.3% C) (Bio-Rad, USA) was prepared so that a concentration gradient between 40% and 60% was formed vertically. The denaturants used at this time were 7M urea and 40% (w/v) formamide (Sigma, USA). Fill the D-code system with about 7ℓ of TAE buffer (20 mM Tris, 10 mM acetic acid, 0.5 mM EDTA, pH 8.0), 2Xloading dye (0.05% bromophenol blue, 0.05% xylene cyanol, 70% glycerol) and PCR product Electrophoresis was performed at 50V for 800 minutes by mixing the same amount. The polyacrylamide gel after electrophoresis was stained in Redsafe (Intron, Korea) solution for 15 minutes, and then a specific band appeared. The band intensities of the DGGE results were analyzed by histogram and digitizing the images using GelCompar2 (Bionumeric, Belgium).

As a result, as can be seen in Figure 2, it was confirmed that the representative harmful strain S. aureus was reduced depending on the treatment of the fermented product of the GFC_1220 strain.

<Experimental Example 4> Anti-inflammatory test: Nitric Oxide (NO)

The degree of inhibition of nitric oxide was measured to confirm the anti-inflammatory activity effect using the fermented products of Examples and Comparative Examples.

RAW 264.7 cells, a type of macrophage, were equally counted and dispensed at 1.0x10 ⁴ cell/well each in a 24-Well plate using DMEM medium containing 1% penicillin/scraptomycin and 10% FBS (fetal bovineserum), Incubated for 24 hours at 37°C and 5% carbon dioxide. Examples 1-2 and Comparative Examples 1-2 were mixed with the medium at a concentration of 50 (μg/ml) in RAW 264.7 cells cultured for 24 hours, and then 1ml was added to each well and incubated at 37°C and 5% CO ₂ conditions. reacted for 24 hours. At this time, LPS (Lipo poly saccharide), an inflammatory inducing factor expressing NO, was also treated at a concentration of 1 μg/ml and reacted for 24 hours at 37° C. and 5% carbon dioxide. Next, after taking only the supernatant from each well, 100㎖ of the culture solution was taken in a 96 well plate using a Nitric Oxide detection kit for each well, and Griess reagent A (N-1-Naphthylethylenediamine (NEDHC)) 50μl and Griess reagent B After adding 50 μl of (Sulfanilamide) and reacting for 10 minutes, the absorbance was measured at 540 nm using an ELISA plate reader. The concentration of NO in the cell culture medium was calculated by comparison with the standard curve for each concentration of sodium nitrite (NaNO2).

division NO production concentration (μM) positive control 15.1±0.94 negative control group 77.8±1.15 Example 1 14.1±1.08 Comparative Example 1 62.2±0.99

As a result, as shown in Table 1, it was confirmed that the nitric oxide production concentration was lower in the Example compared to the Comparative Example, and thus the nitric oxide production inhibitory effect was excellent. Although the type strain strain of GFC_1220 and the control group has the same scientific name as Lactobacillus gasseri , it can be confirmed that the anti-inflammatory effect of the strain of GFC_1220 provided in the present invention is much better. This is judged by the unique characteristics of the strain itself, which is indicated by the difference in strain. Therefore, Lactobacillus gasseri GFC_1220 ( Lactobacillus gasseri GFC_1220) was previously used in Lactobacillus gasseri . It was confirmed that the strain had an anti-inflammatory effect by inhibiting NO, which could not be confirmed.

These results mean that the fermented product of the GFC_1220 strain (accession number: KCTC13840BP) has an anti-inflammatory effect.

<Experimental Example 5> Anti-inflammatory test: cytokine inhibition

The inflammatory response is regulated by the production and secretion of pro-inflammatory cytokines along with NO. Therefore, in order to investigate the effect of strain lysate on the secretion and expression of inflammatory cytokines, cells were treated with LPS and scalp-derived lactic acid bacteria fermented product at various concentrations, and then the amount of inflammatory cytokines secreted from the culture medium was measured by ELISA It was measured using an assay. In addition, changes in the expression of inflammatory cytokines were confirmed through real-time PCR analysis. As a result, as shown in FIG. 3, it was confirmed that the secretion and expression of IL-1β, IL-6, and TNF-α induced by LPS treatment decreased in the treatment of the fermented product of the GFC_1220 strain (accession number: KCTC13840BP). When the fermented product of the breast milk microorganism GFC_1220 strain (accession number: KCTC13840BP) was treated, it was confirmed that it was significantly reduced even at low concentrations in a concentration-dependent manner. Through these results, it was confirmed that the fermented product exhibits anti-inflammatory effects not only by regulating NO, an inflammatory product, but also by suppressing the secretion and expression of inflammatory cytokines in the LPS-induced inflammatory response.

<Experimental Example 6> Antibacterial efficacy test: MIC test

The degree of antibacterial activity was confirmed using the fermented products of Examples and Comparative Examples.

1. Preparation of evaluation medium

The paper disc method was used as an evaluation method, and for the evaluation of antibacterial activity, harmful standard test strains (Ministry of Food and Drug Safety and MIC test guideline) Escherichia coli (ATCC 8739) and Staphylococcus aureus (ATCC) were used. 6538P), Pseudomonas aeruginosa (ATCC 9027), and Candida albicans (ATCC 10231) were purchased from the Korea Microbial Resources Center (KCTC, Korea) and the Korea Microbial Conservation Center (KCCM, Korea). TSA medium (Tryptic Soy Agar) medium was used for culturing Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa among the standard test strains, and YM medium (Yeast extract Media) medium was used for culturing Candida albicans.

2. MIC test

After preparing an independent nutrient medium (Nutrient Broth) sterilized at 121 ° C. for 15 minutes, each standard test strain was inoculated in an amount of 3X10 ⁵ cfu / ml. Example 1 and Comparative Example 1 were typically set to 1%, 0.5%, 0.25%, 0.125%, 0.0625%, 0.03125%, 0.015625%, 0.0078125% concentration, and inoculated and cultured using a single colony of the test strain. . After the incubation, the absorbance (600 nm) was measured to confirm the result. The antibacterial effect was confirmed at the lowest concentration at which microorganisms were not detected.

Classification (unit: %) Escherichia coli Staphylococcus aureus Pseudomonas aeruginosa candida albicans GFC_1220 0.25 0.125 0.125 0.50 comparative example 0.5 0.5 0.5 -

As a result, as shown in Table 2, the GFC_1220 strain culture was tested against four published standard test strains (refer to the Ministry of Food and Drug Safety and MIC test guideline), Escherichia coli (ATCC 8739), Staphylococcus aureus (ATCC 6538P), The inhibitory effect on Pseudomonas aeruginosa (ATCC 9027) and Candida albicans (ATCC 10231) was confirmed, confirming that the antibacterial effect was excellent. It was confirmed that the type strain strain of the comparative example did not show inhibitory activity against Candida albicans in Lactobacillus gasseri , and it was confirmed that the antibacterial effect of the GFC_1220 strain provided in the present invention was excellent despite the strain having the same scientific name.

Having described specific parts of the present invention in detail above, it will be clear to those skilled in the art that these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. will be. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

Korea Research Institute of Bioscience and Biotechnology KCTC13840BP 20190422

Claims (7)

Induction of skin-microbiome changes (reduction of inflammatory S. aureus strains), reduction of inflammation, novel Lactobacillus gasseri GFC_1220 strain having antibacterial effects (accession number: KCTC13840BP) ).
The novel Lactobacillus gasseri GFC_1220 strain (Accession No.: KCTC13840BP) according to claim 1, wherein the strain is derived from breast milk.
A method for producing a fermented product comprising the steps of inoculating a novel Lactobacillus gasseri GFC_1220 strain (accession number: KCTC13840BP) into a medium containing Maltose, Lactose, Glycine and Inulin and culturing it.
The method of claim 3, wherein the culturing is performed at 32 to 37° C. for 90 to 130 hours.
Fermented product fermented with a novel Lactobacillus gasseri GFC_1220 (Accession Number: KCTC13840BP) strain.
A cosmetic composition comprising the fermented product of claim 5 as an active ingredient.
The method of claim 6, wherein the cosmetic composition is selected from the group consisting of skin-microbiome change induction (reduction of inflammatory S. aureus strains), inflammation reduction, and antibacterial effect. A cosmetic composition characterized by